SNPHF News and Press, Santen Pharmaceutical Co. Ltd.

Santen Pharmaceutical Co., Ltd. (SNPHY) Q1 2022 Earnings Conference Call August 4, 2022 03:30 ET Company Participants Peter Sallstig - Chief Medical Officer Conference Call Participants Presentation Peter Sallstig [Foreign Language] Thank ...

The following slide deck was published by Santen Pharmaceutical Co., Ltd. in conjunction with their 2022 Q3 earnings call. For further details see: Santen Pharmaceutical Co., Ltd. 2022 Q3 - Results - Earnings Call Presentation

The following slide deck was published by Santen Pharmaceutical Co., Ltd. in conjunction with their 2021 Q2 earnings call. For further details see: Santen Pharmaceutical Co., Ltd. 2021 Q2 - Results - Earnings Call Presentation

The following slide deck was published by Santen Pharmaceutical Co., Ltd. in conjunction with their 2021 Q1 earnings call. For further details see: Santen Pharmaceutical Co., Ltd. 2021 Q1 - Results - Earnings Call Presentation

Glaukos (GKOS) has entered into a new development and commercialization license agreement with Santen Pharmaceutical (SNPHF) for the Preserflo MicroShunt (DE-128), superseding the previous agreements between the two parties. Under the new agreement, Glaukos obtains exclusive commercialization...

The following slide deck was published by Santen Pharmaceutical Co., Ltd. in conjunction with their 2021 Q4 earnings call. For further details see: Santen Pharmaceutical Co., Ltd. 2021 Q4 - Results - Earnings Call Presentation

The FDA accepts for review Santen Pharmaceutical Co., Ltd.'s (SNPHF) marketing application seeking approval of cyclosporine topical ophthalmic emulsion, 0.1% for the treatment of severe vernal keratoconjunctivitis, an allergic eye disease common in boys, in young patients ages 4-18.The a...

Opthea has filed proposed terms to raise capital from a U.S. IPO. The firm is developing a treatment for Wet AMD and other eye conditions. OPT has produced impressive Phase 2b efficacy trial results for its lead candidate, so the IPO is worth considering for long-term hold life sc...